Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Receivables (2016 - 2025)

Gsk has reported Receivables over the past 10 years, most recently at $11.5 billion for Q4 2025.

  • Quarterly results put Receivables at $11.5 billion for Q4 2025, up 16.1% from a year ago — trailing twelve months through Dec 2025 was $11.5 billion (up 16.1% YoY), and the annual figure for FY2025 was $11.5 billion, up 16.1%.
  • Receivables for Q4 2025 was $11.5 billion at Gsk, up from $9.9 billion in the prior quarter.
  • Over the last five years, Receivables for GLAXF hit a ceiling of $12.3 billion in Q4 2021 and a floor of $9.7 billion in Q4 2022.
  • Median Receivables over the past 5 years was $10.5 billion (2023), compared with a mean of $10.8 billion.
  • Biggest five-year swings in Receivables: increased 16.91% in 2021 and later fell 21.06% in 2022.
  • Gsk's Receivables stood at $12.3 billion in 2021, then fell by 21.06% to $9.7 billion in 2022, then rose by 7.75% to $10.5 billion in 2023, then decreased by 5.63% to $9.9 billion in 2024, then grew by 16.1% to $11.5 billion in 2025.
  • The last three reported values for Receivables were $11.5 billion (Q4 2025), $9.9 billion (Q4 2024), and $10.5 billion (Q4 2023) per Business Quant data.